AstraZeneca vaccine changes name to Vaxzevria

Australia's regulatory authority has approved a name change for the COVID-19 vaccine AstraZeneca, which will now be known as Vaxzevria.

The Therapeutic Goods Administration (TGA) today approved the name change in an effort to bring the naming conventions of the vaccine in line with the European Union and Canada.

A change of name is the only change made to the vaccine.

READ MORE: Pfizer vaccine to be made available for 16-39 year-olds by next month

All other aspects – including ingredients, dosage, quality control and application – remain unchanged.

The Department of Health said the name change is expected to "alleviate confusion" and to clarify that the virus made by CSL and Seqirus in Melbourne is the same one that is produced internationally.

Looking forward, the name change will help facilitate international recognition for Australians who received the AstraZeneca vaccine.

READ MORE: Greater uptake of AstraZeneca vaccine at Sydney community clinics

The AstraZeneca vaccine was approved for use in Australia in late February. (Sven Hoppe/dpa via AP, File)

"At this stage, it is estimated that supply in Australia of the VAXZEVRIA-branded product will commence in late 2021," the TGA said in a statement.

"Once supply of the vaccine commences under the new name, the vaccine will no longer be supplied under the original name.

"Some stock with the original name may still be in use after the name change."

In a statement, a spokesperson for AstraZeneca said the change of name will make the vaccine produced locally here in Australia valid for travel to Europe.

READ MORE: Moderna COVID-19 vaccine provisionally approved by the TGA for use in Australia

Empty vials of the AstraZeneca COVID-19 vaccine are seen at the vaccination unit of the Italian Defence, as part of COVID-19 vaccinations plan for the military personnel, in Rome, Italy.

"Use of the Vaxzevria brand name should help simplify international travel for people vaccinated with AstraZeneca's vaccine. The vaccine has previously received emergency authorisation from the World Health Organisation," the spokesperson said.

"As such Vaxzevria, including Vaxzevria produced at CSL in Australia, is a valid vaccination for travel to Europe."

The spokesperson also reassured residents that no change was being made to the actual vaccine.

"AstraZeneca's COVID-19 vaccine is the same product wherever it is made," the spokesperson said.

"All manufacturing around the world is conducted using the same stringent manufacturing process and each batch passes over 60 quality tests as part of our global robust quality assurance process."

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *